Analyst consensus rating
Kyntra Bio Analyst Rating: Buy
KYNB is rated Buy by 2 analysts with a $39.00 target. As of 2026-08-25.
Direct answer
Kyntra Bio's consensus rating is Buy.
2 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $39.00.
Forecast evidence checked August 25, 2026.
Get free Kyntra Bio email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $7.98
- Average price target
- $39.00
- High price target
- $43.00
- Low price target
- $35.00
- Low target gap
- +338.6%
- Target upside
- +388.7%
- High target gap
- +438.8%
- Target range width
- 100.3%
- Consensus rating
- Buy
- Analysts
- 2
- Evidence date
- August 25, 2026
- Valid through
- September 1, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Kyntra Bio?
Kyntra Bio has a verified Buy consensus. The same dataset has an average price target of $39.00.
How far are Kyntra Bio's low and high targets from the recorded price?
The low target implies +338.6%, while the high target implies +438.8%.
How many analysts are included in Kyntra Bio's consensus?
The verified consensus includes 2 analysts.
How is Kyntra Bio's target upside or downside calculated?
The average target of $39.00 is divided by the recorded price of $7.98, then one is subtracted to produce +388.7%. This does not guarantee a future return.
When was Kyntra Bio's analyst forecast verified?
The data was verified on 2026-08-25. The dataset is valid through 2026-09-01.